We support drug and product preclinical development with trusted GLP and non-GLP scientific services with in vitro and in vivo rodent/non-rodent models.
Bridging innovation and preclinical development to advance healthier products.
of reports delivered before deadlines
studies performed during the last 5 years
First ERBC site established in Italy, then the second one in France in 1973.
sites with BSL1, BSL2 and BSL3 laboratories.
ERBC, a leading preclinical Contract Research Organization (CRO), provides a comprehensive range of preclinical services, including discovery, toxicology, safety pharmacology, pharmacokinetics, bioanalytics, and translational research together with innovated models such as avian-PDX and Non-Human Primates (NHP). These services are tailored to support the pharmaceutical, biotechnology, chemical, agro-chemical, cosmetic and medical device industries.
Our studies are run at Good Laboratory Practice (GLP) and Good Clinical Practices (GCP) facilities to ensure regulatory compliance and high-quality results.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs. Yes, our expertise includes preparing comprehensive regulatory packages, such as SEND-compliant datasets, to support IND and NDA submissions.
We offer end-to-end support, from early-stage discovery through to clinical trial material manufacturing, ensuring seamless progression and adherence to timelines.